SEC Tracker
Get the app

Volitionrx VNRX

VolitionRX Ltd. (VNRX) filed an amended Form 8-K to report a strategic partnership with a major pharmaceutical company. This collaboration is expected to significantly boost VolitionRX's commercial prospects and accelerate the development of its novel cancer diagnostic platform, which could drive substantial revenue growth and shareholder value in the coming years.

Form
8-K/A
Filed
Importance
Routine

Open in the appGet the appView on EDGAR

Get an email when Volitionrx files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2835 and related industry codes: the same peer list as the financial tables.

  1. Gyre Therapeutics GYRE public float $73M, Jun 30, 2025
  2. Oncolytics Biotech ONCY public float $72M, Jun 30, 2025
  3. Seres Therapeutics MCRB public float $72M, Jun 30, 2025
  4. Macrogenics MGNX public float $74M, Jun 30, 2025
  5. Inovio Pharmaceuticals INO public float $74M, Jun 30, 2025